

1 **Combined prenatal *Lactobacillus reuteri* and ω -3 supplementation**
2 **synergistically modulates DNA methylation in neonatal T helper cells**

3 Johanna Huoman PhD¹, David Martínez-Enguita MSc², Elin Olsson MSc², Jan Ernerudh MD
4 PhD³, Lennart Nilsson MD PhD⁴, Karel Duchén MD PhD⁴, Mika Gustafsson PhD^{2*} and Maria
5 C Jenmalm PhD^{1*}

6 ¹ Division of Inflammation and Infection, Department of Biomedical and Clinical Sciences,
7 Linköping University, Linköping, Sweden

8 ² Department of Physics, Chemistry and Biology, Linköping University, Linköping, Sweden

9 ³ Department of Clinical Immunology and Transfusion Medicine, Department of Biomedical
10 and Clinical Sciences, Linköping University, Linköping, Sweden

11 ⁴ Allergy Center, Department of Biomedical and Clinical Sciences, Linköping University,
12 Linköping, Sweden

13

14 *shared senior authorship

15

16 **Corresponding author:** Johanna Huoman, PhD
17 Division of Inflammation and Infection
18 Department of Biomedical and Clinical Sciences
19 Faculty of Medicine and Health Sciences
20 Linköping University
21 Lab 1, Building 420, entrance 68, level 12
22 581 83 Linköping, Sweden
23 E-mail: johanna.huoman@liu.se
24 Phone: +46 76 069 63 38

25

26 **Word count:** 3491 words (Introduction, Results and Discussion. Including Methods, 5841
27 words)

28 **Number of figures:** 6 Figures

29 **Number of tables:** 2 Tables

30 **Material in electronic repository:** 12 Supplementary Figures, 11 Supplementary Tables,
31 mainly collected in Supplementary Appendix.

32 **NOTE:** This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

33 **ABSTRACT**

34 **Background:** Environmental exposures may alter DNA methylation patterns of T helper cells.
35 As T helper cells are instrumental for allergy development, changes in methylation patterns
36 may constitute a mechanism of action for allergy preventive interventions. While epigenetic
37 effects of separate perinatal probiotic or ω -3 fatty acid supplementation have been studied
38 previously, the combined treatment has not been assessed. We aimed to investigate
39 epigenome-wide DNA methylation patterns in cord blood samples from children in a
40 randomised double-blind placebo-controlled allergy prevention trial using pre- and postnatal
41 combined *Lactobacillus reuteri* and ω -3 fatty acid treatment. To this end, >866 000 CpG sites
42 (MethylationEPIC 850K array) in cord blood CD4+ T cells were examined in samples from all
43 four study arms (double-treatment: n=18, single treatments: probiotics n=16, ω -3 n=15, and
44 double placebo: n=14). Statistical and bioinformatic analyses identified treatment-associated
45 differentially methylated CpGs and genes, which were used to identify treatment-induced
46 network modules. Pathway analyses inferred biological relevance, and comparisons were
47 made to an independent allergy data set.

48 **Results:** Comparing the active treatments to the double placebo group, most differentially
49 methylated CpGs and genes were hypermethylated, suggesting induction of transcriptional
50 inhibition. The double-treated group showed the largest number of differentially methylated
51 CpGs, of which many were unique, suggesting synergy between interventions. Clusters within
52 the double-treated network module consisted of immune-related pathways, including T cell
53 receptor signalling, and antigen processing and presentation, with similar pathways revealed
54 for the single-treatment modules. CpGs derived from differential methylation and network
55 module analyses were enriched in an independent allergy data set, particularly in the double-
56 treatment group, proposing treatment-induced DNA methylation changes as relevant for
57 allergy development.

58 **Conclusion:** Prenatal *L. reuteri* and/or ω -3 fatty acid treatment results in hypermethylation
59 and affects immune- and allergy-related pathways in neonatal T helper cells, with potentially

60 synergistic effects between the interventions and relevance for allergic disease. Further
61 studies need to address these findings on a transcriptional level, and whether the results
62 associate to allergy development in the children. Understanding the role of DNA methylation
63 in regulating effects of perinatal probiotic and ω -3 interventions may provide essential
64 knowledge in the development of efficacious allergy preventive strategies.

65

66 **Key words (max 10):** allergy prevention, combined intervention, cord blood, CD4+ T cells,
67 DNA methylation, *Lactobacillus reuteri*, MethylationEPIC 850K, ω -3 fatty acids, prenatal,
68 postnatal

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83 INTRODUCTION

84 Present-day increases in allergy prevalence in urbanised societies may be caused by the
85 extensive loss of diverse microbial exposures due to changed lifestyle habits, thereby affecting
86 development of appropriate immune responses.^{1,2} This is particularly important throughout the
87 perinatal period, when maternal exposures during pregnancy and breastfeeding lay the
88 foundations of, and influence, immune development of the foetus and the newborn child.³⁻⁶
89 Hence, the maternal influence on the foetal immune system is significant, and the composition
90 of both the maternal diet and her commensal microbiome is crucial in the process.^{7,8}

91 By supplementing pregnant women, with a high propensity of having an allergic child, during
92 pregnancy and lactation with ω -3 fatty acids and probiotics, it may be possible to modulate the
93 foetal immune system towards tolerance.^{7,9,10} In Westernised societies the dietary fatty acid
94 intake favours ω -6 over ω -3 fatty acids^{11,12}, thereby promoting production of pro-inflammatory
95 mediators, such as prostaglandins and leukotrienes¹³, and possibly sustaining allergic
96 inflammation.¹⁰ However, by ω -3 supplementation this ratio may be altered and promote
97 downstream production of immunoregulatory mediators.¹⁰ ω -3 fatty acids may dampen allergic
98 inflammation by inhibiting effects of IL-4 and IL-13, as well as by preventing isotype switching
99 of B cells to IgE-antibodies.⁷ Indeed, prenatal ω -3 intervention attenuated IL-4 and IL-13 levels
100 in cord blood¹⁴, and decreased the risk of developing asthma in the offspring.¹⁵ Previously, we
101 have investigated the effects of pre- and postnatal ω -3 supplementation, demonstrating lower
102 prevalence of sensitisation and IgE-associated eczema throughout the first year of life¹⁶, and
103 a decreased risk of developing any IgE-associated disease up to two years of age¹⁷, in ω -3
104 compared to placebo-treated children. Several studies point at altered gut microbiomes in
105 children developing allergies¹⁸⁻²³, suggesting that increasing gut microbial diversity by e.g.
106 probiotic intervention may be helpful in allergy prevention.²⁴ Lactobacilli, a commonly used
107 family of probiotic bacteria, induce both innate and adaptive immunostimulatory responses,
108 apart from improving barrier integrity and modulating gut microbiota composition.²⁵ We have
109 previously shown allergy preventive effects on IgE-associated eczema upon supplementation

110 with *Lactobacillus reuteri*.²⁶ Interestingly, children whose mothers had allergic symptoms
111 revealed the greatest benefits of the *L. reuteri* treatment²⁶, whereas ω -3 treatment provided
112 most benefit to children whose mothers did not have allergic symptoms.^{16,17} This suggests that
113 combining the treatments could benefit allergy prone children regardless of maternal allergy
114 status, and possible synergistic effects of the immunostimulating probiotics and the
115 immunomodulatory ω -3 fatty acids could occur. However, this has thus far not been studied.

116 A suitable way to evaluate the effects of supplemental interventions would be to study
117 epigenetic modifications, since they regulate transcriptional accessibility of genomic regions in
118 response to environmental stimuli.²⁷ DNA methylation of CpG sites is considered the most
119 stable epigenetic modification, and is known to regulate the differentiation of T helper cells²⁸,
120 cells that are central in development of allergic disease.²⁷ Indeed, differential DNA methylation
121 patterns associate with development of sensitisation^{29,30}, asthma^{31,32} and food allergies^{33,34} in
122 children and adolescents. Epigenetic studies of prenatal fatty acid intervention have shown
123 effects on histone modifications³⁵, while others report conflicting results on DNA methylation
124 patterning.^{36,37} A study on epigenomic modulation of combined *L. rhamnosus*
125 *GG/Bifidobacterium lactis* in obesity³⁸ revealed general hypomethylation, in line with findings
126 from our previous study investigating *L. reuteri* in allergy prevention.³⁹ In newborns whose
127 mothers had been supplemented with *L. reuteri* throughout the last month of pregnancy, this
128 loss of methylation in CD4+ cord blood cells was prominent in genes related to immune
129 activation.³⁹ This indicates that treated children received a head-start in their immune
130 maturation, which hence may affect the development of allergic disease. However, in the
131 context of combining probiotics and ω -3 fatty acids, neither clinical outcomes nor epigenetic
132 effects have yet been studied.

133 In the on-going PROOM-3 trial (PRObiotics and OMega-3, ClinicalTrials.gov-ID:
134 NCT01542970), the allergy preventive effects of combined *L. reuteri* and ω -3 fatty acids
135 supplementation, from mid-pregnancy throughout the first year of life of the child, are studied.
136 In this paper, we examined epigenome-wide DNA methylation patterns in cord blood CD4+

137 cells from the PROOM-3 cohort. Our hypothesis was that the earlier initiated probiotic
138 treatment will lead to more prominent effects on DNA hypomethylation in immune-related
139 genes compared to the previous study.³⁹ Likewise, we hypothesised that ω -3 fatty acid
140 supplementation will lead to hypomethylation of immune-related sites, and possibly work
141 synergistically with the probiotic intervention to cause the greatest differential methylation in
142 immunological pathways. Our findings indicate that the epigenome is modulated by the
143 prenatal treatment with probiotics and ω -3 fatty acids, which may have implications for
144 developing and improving future allergy prevention strategies.

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160 **RESULTS**

161 **Differential DNA methylation analyses reveal mainly hypermethylated CpGs and genes**
162 **upon supplementation with *L. reuteri* and/or ω -3 fatty acids**


163 Comparisons of demographic variables revealed no differences between the treatment groups,
164 except for a higher proportion of females in the ω -3 single active treatment (P ω) group (Table
165 1). This lead us to exclude the sex chromosomes from further analyses, as retaining them
166 might affect downstream results. Thereafter, we pursued multidimensional scaling (MDS)
167 analyses to investigate inherent differences between the three active treatment groups, the
168 double *L. reuteri* and ω -3-treated group (L ω), the *L. reuteri* single-treated group (LP) and the
169 ω -3 single-treated group (P ω), compared to the double placebo group (PP). These analyses
170 revealed distinct differences between the treated and untreated groups (Figure 1A-C),
171 indicating treatment-associated changes at the epigenome level. We then proceeded to
172 analyse differential DNA methylation, using an FDR-adjusted p-value threshold of <0.1 along
173 with a mean methylation difference (MMD) of > 5% to define differentially methylated CpGs
174 (DMCs). The double-treated L ω group demonstrated the highest number of DMCs compared
175 with the single active treatment groups (L ω : 1659, LP: 1246 and P ω : 984 CpG sites,
176 respectively, Table 2). A majority of the DMCs were hypermethylated (58-70%, Table 2, Figure
177 1 D-E, Table S1) in all three comparisons, suggesting that prenatal treatment with probiotics
178 and/or ω -3 fatty acids foremostly leads to transcriptional inhibition. To investigate the biological
179 impact of these findings, the DMCs were mapped to their corresponding differentially
180 methylated genes (DMGs), which thereafter were utilised for pathway enrichment analyses.
181 The double-treated L ω group contained 794 genes compared to 620 and 494 genes in the
182 single-treated LP and P ω groups, respectively (Figure 2, Table S2), and 72 genes were shared
183 for all three comparisons (Figure 2, Table S3). Pathway enrichment analyses of the DMGs in
184 the respective comparisons revealed 87 pathways for the L ω group, including immune-related
185 pathways such as PI3K-Akt and MAPK signalling,

186 **Table 1.** Demographic characteristics of children with available cord blood samples from the PROOM-
187 3 study.

Intervention group	Lω	LP	Pω	PP
<i>Group description and size</i>	<i>L. reuteri</i> + ω -3 PUFA n=18	<i>L. reuteri</i> + Placebo n=16	Placebo + ω -3 PUFA n=15	Placebo + Placebo n=14
<i>Female</i>	6/18 (33%)	7/16 (44%)	12/15 (80%)*	3/14 (21%)
<i>Birth week</i>	39.5 (39.0-41.0)	40.0 (38.8-40.2)	40.0 (40.0-41.0)	40.0 (39.0-41.0)
<i>Treatment duration</i>	19.0 (19.0-21.2)	19.5 (19.0-20.0)	20.0 (19.5-21.0)	20.0 (19.0-20.8)
<i>Maternal age (birth)</i>	31.0 (29.0-32.8)	32.0 (30.0-33.2)	32.0 (29.0-33.0)	30.0 (28.2-32.5)
<i>Caesarean delivery</i>	3/17 (18%)	0/16 (0%)	1/15 (7%)	1/14 (7%)
<i>Birth weight (kg)</i>	3.8 (3.6-3.9)	3.5 (3.3-3.9)	3.9 (3.7-4.1)	3.8 (3.6-4.1)
<i>Birth height (cm)</i>	51.0 (50.0-52.0)	51.5 (49.8-52.2)	51.0 (50.5-52.5)	51.0 (50.0-52.0)
<i>Maternal atopy</i>	14/18 (78%)	11/16 (69%)	7/15 (47%)	8/14 (57%)
<i>Paternal atopy</i>	9/18 (50%)	9/16 (56%)	9/15 (60%)	11/14 (79%)
<i>Siblings</i>	1.0 (0.0-1.0)	1.0 (0.0-1.2)	1.0 (0.0-1.5)	0.0 (0.0-1.0)
<i>People in home</i>	4.0 (3.0-4.0)	4.0 (3.0-5.0)	3.0 (3.0-4.0)	3.5 (3.0-4.0)
<i>Smoking in home</i>	0/18 (0%)	0/16 (0%)	0/12 (0%)	1/14 (7%)
<i>Breastfeeding (at 3 months)</i>	15/18 (83%)	12/16 (75%)	9/12 (75%)	12/14 (86%)
<i>Antibiotics (during first 3 months)</i>	1/15 (7%)	1/14 (7%)	0/10 (0%)	0/11 (0%)
<i>Pets in home (at 3 months)</i>	4/18 (22%)	5/16 (31%)	3/11 (27%)	1/13 (8%)
<i>Naïve CD4+CD45RA+ cells (%)</i>	95.6 (94.6-97.4)	96.6 (95.7-97.1)	95.7 (95.3-97.3)	95.9 (94.5-96.9)
<i>Memory CD4+CD45RA- cells (%)</i>	4.4 (2.6-5.4)	3.4 (2.9-4.3)	4.3 (2.7-4.7)	4.1 (3.1-5.5)

188
189 Demographic variable information was retrieved from parentally reported questionnaire data at the three month
190 follow-up. Continuous variables are expressed as medians with interquartile ranges and were analysed using the
191 Shapiro-Wilk's test of normality followed by Levene's test of equal variances and the Kruskal-Wallis H test. For the
192 categorical variables, the Pearson χ^2 test was performed and the data is presented as n/N (%). *denotes significantly
193 more females than males in the P ω group, p=0.01. L – *Lactobacillus reuteri*, ω – ω -3 fatty acids, P – placebo.

194 **Figure 1.**



195 **Figure 1.** Graphical representations of multidimensional scaling (MDS) analyses are shown in panels
 196 A-C for the double active (L ω) and single active treatment groups (LP, P ω), respectively, in comparison
 197 to the double placebo group (PP). Red dots represent the active treatment group, blue dots the placebo
 198 group. In panels D-E, volcano plots illustrate the distribution of DMCs when comparing each of the active
 199 treatment groups to the double placebo group (PP). DMCs are defined as having an MMD of > 5% along
 200 with an FDR-corrected p-value of < 0.1, and are depicted as red dots. DMC – differentially methylated
 201 CpG, MDS – multidimensional scaling, MMD – mean methylation difference, L – *Lactobacillus reuteri*,
 202 ω – ω -3 fatty acids, P – placebo.


203
 204 Phospholipase D signalling and T cell receptor signalling (Table S4). The LP group revealed
 205 20 pathways, amongst others the Rap 1, Phospholipase D signalling and Th17 differentiation
 206 pathways (Table S5), whereas the P ω group did not reveal any pathways at all.

207 **Table 2.** Results from the differential methylation analyses, comparing the active treatments vs. the
 208 double placebo group.

Intervention group	L ω vs. PP	LP vs. PP	P ω vs. PP
<i>DMCs</i>	1 659	1246	984
Hypomethylated CpGs	576 (35%)	380 (30%)	415 (42%)
Hypermethylated CpGs	1083 (65%)	866 (70%)	569 (58%)
<i>DMGs</i>	794	620	494
Hypomethylated genes	247 (31%)	204 (33%)	184 (37%)
Hypermethylated genes	524 (66%)	405 (65%)	295 (60%)
Mixed methylation genes	23 (3%)	11 (2%)	15 (3%)

209
 210 Proportions of hypo- and hypermethylated CpGs and genes, from the differential DNA methylation analyses
 211 comparing the active treatment groups vs. the double placebo group, are presented as n (% of total). DMCs
 212 – differentially methylated CpGs, DMGs – differentially methylated genes, L – *Lactobacillus reuteri*,
 213 ω – ω -3 fatty acids, P – placebo.

214 **Figure 2.**




222 **Figure 2.** A graphic representation of overlapping DMGs between the different comparisons. The sets
 223 represent the different comparisons, and the intersectional sizes show the number of overlapping genes
 224 between the comparisons. Dark blue represents the double-treated group, light blue the *L. reuteri* single-
 225 treated group and coral blue the ω -3 single-treated group. L – *Lactobacillus reuteri*, ω – ω -3 fatty acids,
 226 P – placebo.

227 **Network analyses show immune-related pathways being affected by the interventions**

228 As a means to further elaborate on the wider biological context in which the supplementation-
229 induced DMGs act, the DMGs were mapped onto a protein-protein interaction map (STRING-
230 db) to study putative interactions in a network context. The most interconnected modules were
231 derived from DMGs identified by four module discovery methods from the MODifieR⁴⁰ package.
232 This approach narrowed down the number of supplementation-induced DMGs to 170, 100 and
233 87 genes for the L ω , LP and P ω comparisons, respectively (Tables S6-S8). High-confidence
234 interactions from the respective modules are displayed in Figure 3 and Figures S2-3. Of the
235 170 genes identified in the double-treated L ω module, six genes were considered highly
236 connected (exhibiting 10 or more connections to other module genes), and could be
237 considered important hubs within the network: *FYN*, *GNB5*, *SNAP23*, *LAMC1*, *IL6* and *RAF1*
238 (Figure 3). All genes but *IL6* were hypermethylated. Inspecting the network module for
239 biologically relevant clusters, pathway enrichment analyses of those clusters revealed that
240 supplementation with both *L. reuteri* and ω -3 affects pathways such as T cell receptor
241 signalling, antigen processing and presentation as well as TGF- β signalling (Figure 3, Figure
242 S3), clusters that were also observed in corresponding analyses of the single-treated groups
243 (Figures S1-2, S4-5).

244 To further evaluate common and unique features of the obtained supplementation modules,
245 comparisons were made between the three treatment groups. While 10 genes were shared
246 between all three comparisons, 24, 14 and 10 genes overlapped when comparing the L ω group
247 to the *L. reuteri* single-treated (LP) group, the L ω to the ω -3 single-treated (P ω) group and the
248 single-treated groups (LP vs. P ω) to each other, respectively (Figure 4A, Table S9). Genes
249 common to all treatment groups related to cellular adhesion and extracellular matrix-receptor
250 interaction pathways, whereas the comparisons between the single-treated groups revealed
251 no significant pathways. Compared to the L ω double-treated group, overlaps to the single-
252 active P ω group related to T cell receptor signalling and other related signal transduction
253 pathways, while overlaps to the LP group included Ca²⁺ signalling and O-glycan biosynthesis

254 **Figure 3.** Lw vs. PP




255 **Figure 3.** Visualisation of the consensus module created with the DMGs from the differential methylation
 256 comparison between the double-treated *L.reuteri*/ω-3 (Lw) and the double placebo (PP) group. Nodes
 257 represent genes and connecting lines represent protein-protein interactions (STRING combined score
 258 > 0.7) within the network. Red nodes illustrate hypermethylated genes, blue nodes indicate
 259 hypomethylated genes and both colours denote mixed methylation patterns. Black lines enclose
 260 biologically relevant clusters identified by bioinformatic pathway enrichment analyses. Nodes marked
 261 with * are also present in an independent allergy data set (described later in the paper). DMGs –
 262 differentially methylated genes, L – *Lactobacillus reuteri*, ω – ω-3 fatty acids, P – placebo.

263 (Figure 4A), pathways which are relevant for proper T cell function. The largest number of
 264 unique genes were revealed for the double active Lw treatment group (122 genes), which were


265 mainly biologically related to T cell receptor signalling and related signal transduction
 266 pathways, TNF and NFκB signalling as well as asthma (Figure 4B). The single-treated groups
 267 showed similar numbers of unique genes (LP: 56 genes, Pw: 53 genes), which related to
 268 Th1/2/17 helper cell differentiation and asthma amongst other pathways for the LP group, while
 269 yet again no relevant pathways were discovered for the Pw treatment group. Hence, combined
 270 probiotic and ω-3 supplementation seems to have synergistic effects at the network level
 271 compared to the single treatments.

272 Further evaluation of the direction of methylation in the shared genes revealed that treatment
 273 with either *L. reuteri* or ω-3 fatty acids led to consistent methylation patterns in most of the
 274 genes when compared to the double-treated Lω group (Figure 5A-B, Table S9). This pattern
 275 was even more distinct comparing the single active treatment groups, where only one gene
 276 revealed different methylation patterns between the groups (Figure 5C). In the comparison
 277 between all three treatment groups, however, the patterning of approximately half the genes
 278 were similar, whereas the single active groups exhibited different and still distinct shared DNA
 279 methylation patterns with the Lω group (Figure 5D).

280 **Figure 4.**



2 **B**




291

292

293

294 **Figure 4.** Venn diagrams illustrating the degree of overlap and uniqueness for the obtained genes from
 295 the three network modules for the double active treatment (Lw vs. PP) and the single active treatment
 296 (LP vs. PP, Pω vs. PP) comparisons. In panel A. the number of common genes from the overlap are
 297 displayed for each comparison is shown, with corresponding gene names denoted in italics, and
 298 selection of related pathways in bold. No relevant pathways were revealed for the shared genes of the
 299 LP vs. PP and Pω vs. PP comparisons. In panel B. the number of genes that are unique for each
 300 comparison are displayed along with a selection of corresponding related pathways. No pathways of
 301 relevance were revealed for the unique genes from the Pω vs. PP comparison. L – *Lactobacillus reuteri*,
 302 ω – ω-3 fatty acids, P – placebo.

303 **Figure 5.**



304 **Figure 5.** River plots illustrating the methylation status for overlapping genes being shared between the
 305 double-treated Lw group and A. the single-treated probiotic (LP vs. PP), and B. ω -3 treated (P ω vs. PP)
 306 group. Panel C. illustrates comparisons between the single treated groups (LP and P ω vs. PP) and D.
 307 shows the comparison between all treatment groups. Genes are represented as flows of size
 308 proportional to number of genes within their methylation status in a particular set, and differences
 309 between sets are shown as connections between flows. The respective gene names are denoted next
 310 to each flow. Red represents hypermethylation, blue hypomethylation and green a mixed methylation
 311 pattern. The number of genes in the respective flows are denoted in the graph. L – *Lactobacillus reuteri*,
 312 ω – ω -3 fatty acids, P – placebo.

313 **Differentially methylated CpGs in the active treatment groups were enriched in an**
 314 **independent allergic disease data set**

315 As no information is as yet available on allergy development for the children included in this
 316 study, we pursued enrichment analyses on DMCs extracted from the differential DNA


317 methylation analyses for all three comparisons, and compared them to DMCs of a publicly
318 available allergy data set, studying DNA methylation patterns in CD4+ T cells of adults with
319 seasonal allergic rhinitis (8 patients vs. 8 controls). Indeed, for all three comparisons, a
320 substantial number of DMCs were significantly enriched within the allergy data set (Lw: 91,
321 $p=4.7e^{-28}$, LP: 47, $p=2.6e^{-11}$ and Pw: 56 CpGs, $p=1.9e^{-17}$, Figure 6A). Investigating involved
322 pathways of the genes from these DMCs, few or no pathways emerged (results not shown).
323 Three CpG sites overlapped between the three groups (in the genes *MYOF*, *C6orf123* and
324 *PTPRN2*), while additionally 8 and 11 CpGs were common comparing the the double-treated
325 Lw group to the single-treated LP and Pw groups, respectively, and 4 CpGs were overlapping
326 between the single-treated groups (Table S10).

327 As some results from the network analyses indicated involvement of network genes in allergy-
328 related pathways, we additionally pursued comparisons of our DMCs from the consensus
329 modules for all three comparisons to the above mentioned allergy data set. Enrichment
330 analyses revealed that there was a significant overlap between our DMCs identified by the
331 double-treated Lw network module and allergic disease (9 genes, $p=0.00021$, Figure 6B), while
332 no significant enrichments were revealed for the single-treated groups. Examining these nine
333 genes within the Lw module in more detail, four were hypomethylated (*TNF*, *FAS*, *TRAT1* and
334 *HIVEP3*), while five were hypermethylated (*SLC44A2*, *MFGE8*, *EPHA4*, *BCL7A* and
335 *RAB11FIP1*), and seven of these genes were present within the connected components of the
336 network (all but *HIVEP3* and *RAB11FIP1*, Figure 3, genes marked with asterisks). Six out of
337 seven genes were furthermore located to the central parts of the network, mainly involved in T
338 cell receptor signalling and antigen processing and presentation. Comparing the direction of
339 methylation to the independent allergy data set, four genes exhibited the opposite direction of
340 patterning (*HIVEP3*, *TRAT1*, *BCL7A* and *SLC44A2*), while the DNA methylation patterning of
341 the remaining genes were identical between the groups (Figure S6).

342

343

344 **Figure 6.**



345

346 **Figure 6.** Enrichment analyses relating DMCs from A. differential DNA methylation analyses and B.

347 network analyses for all three comparisons, to DMCs from a study investigating DNA methylation

348 patterns in adults with seasonal allergic rhinitis. Panel A. shows treatment DMC overlaps with allergy

349 DMCs. Panel B. shows consensus module gene associated DMC overlaps with allergy DMCs. The

350 number of overlapping DMCs is shown at the bottom of the bars (n). A one-sided Fisher's exact test

351 was used for the enrichment analyses. Computed P-values represent the enrichment significance, while

352 the fold enrichment illustrates how over-represented the overlap is, compared to what would be

353 expected by chance for the given background.

354

355

356

357

358

359

360

361

362 DISCUSSION

363 The role of perinatal combined allergy prevention interventions on epigenetic patterning in T
364 helper cells has hitherto been unknown. In this paper, we set out to assess the epigenome-
365 wide effects on cord blood CD4+ cells of combined maternal probiotic and ω -3 intervention
366 during the latter half of pregnancy. Indeed, we show that prenatal supplementation affects the
367 epigenome of T cells from cord blood in the neonates substantially, and differently so
368 depending on the treatment combination.

369 The main finding of this study was that the largest treatment-induced effect on the epigenome
370 was revealed in the L ω double active treatment group, and that regardless of treatment
371 hypermethylation was the main outcome. The network analyses revealed the same pattern in
372 the created intervention modules, and the genes shared between the comparisons as well as
373 the performed network analyses revealed common biological pathways. The L ω module made
374 up the highest number of genes while fewer, but still significant, numbers were revealed in the
375 single-treated LP and P ω modules. This indicates that there might be some synergistic effects
376 of the double treatment. Although the number of shared genes from the networks were limited
377 and the methylation patterns of the genes were only partly similar, this further suggests that
378 the combined treatment may modulate the epigenetic response differently from the single
379 treatment groups. Probiotics may affect DNA methylation either by the production of
380 metabolites downstream of short chain fatty acids, which are indispensable co-factors for
381 proper functioning of enzymes such as DNA methyltransferases, or directly by modifying the
382 actions of the same enzymes.⁴¹ Similarly, ω -3 fatty acid intervention may alter DNA
383 methyltransferase activity⁴² and regulation of transcription factor activity.⁴³ However, how the
384 combination of the two treatments act on a molecular level still needs further elaboration.
385 Examining the genes that were unique to the respective comparisons, the L ω and LP groups
386 featured large numbers of immune-related pathways, yet again involving signal transduction
387 pathways important for T cell signalling, but also T helper cell differentiation and asthma. This
388 is particularly interesting, and future studies on these children will have to settle whether

389 induced DNA methylation differences are associated with the development of allergic disease.
390 Altogether, our findings propose that the interventions modulate the epigenome, and more
391 specifically so in pathways that are of general importance for proper T cell development and
392 function.

393 To further understand the impact of the prenatal intervention on the epigenome, genes that
394 were highly connected within the module network were scrutinised in detail. In the double-
395 treated Lw group, six genes had more than 10 connections to other genes within the network.
396 One of the genes was *FYN*, a non-receptor tyrosine-protein kinase involved in the downstream
397 signal transduction pathway of the T cell receptor, regulating amongst other things T cell
398 activation and differentiation.⁴⁴ In this study, *FYN* was hypermethylated, suggesting that the
399 gene would be transcriptionally silenced by treatment and thereby also downregulating
400 putative protein functions. Another gene of interest was the hypomethylated inflammatory
401 cytokine gene *IL6*. IL-6 is heavily involved in the development and maintenance of
402 inflammation, by inducing both innate and adaptive inflammatory immune responses.⁴⁵ In
403 modulation of the latter, IL-6 regulates both proliferation and cytokine responses of CD4+ cells
404 by inducing JAK/STAT, MAPK and PI3K-Akt signalling pathways, and downstream effects of
405 this activation have been implicated in development of asthma. On an epigenomic level,
406 hypomethylation of IL-6 has been shown in children with peanut allergy⁴⁶, and it has also been
407 associated to worse lung function in asthmatic children.⁴⁷ Furthermore, in the first 6-12 months
408 of life, the *IL6R* gene was hypomethylated in a pre-and postnatal probiotic intervention study
409 investigating development of obesity in children.³⁸ As we are still collecting information about
410 development of allergic disease such as asthma in the present PROOM-3 study, the long term
411 implications of this finding are unknown. It is possible, however, that the intervention enables
412 transcriptional accessibility of this gene, and hence equips the child with early inflammatory
413 capacity. This notions is in line with the observed overlap of DMCs from the Lw consensus
414 module with the publicly available allergy data set. Three hypomethylated genes from the T
415 cell receptor signalling cluster were of particular interest: *TNF*, *FAS* and *TRAT1*. The T cell

416 receptor-associated transmembrane adaptor protein TRAT1 is known to stabilise the T cell
417 receptor/CD3 complex, and may thereby modulate downstream signal transduction and
418 promote T cell function.^{48,49} TRAT1 was hypomethylated in the Lw group, whereas it was
419 hypermethylated in the independent allergy data set, indicating that the combined intervention
420 may enable proper T cell signalling propagation into the cell. While the cytokine tumor necrosis
421 factor (TNF) may not only promote inflammatory responses and induce proliferation of both
422 naïve and memory T cells, it may also drive apoptosis of effector T cells.⁵⁰ Similarly, the TNF-
423 related FAS receptor may also induce apoptosis of cells by binding to FASL, leading to
424 recruitment of caspase-8 and -10 and subsequent commencement of programmed cell
425 death.⁵¹ This process is of crucial importance in the establishment of peripheral tolerance, and
426 as TNF and FAS were hypomethylated in the Lw comparison, this suggests that anti-
427 inflammatory effects of TNF and FAS could be promoted by the supplementation of probiotics
428 and ω -3 prenatally. However, further studies on transcriptional and protein levels of these
429 mediators, along with functional studies in relation to allergy development should shed light on
430 the relevance of these findings upon prenatal interventions.

431 One quite surprising finding of this study was that, in contrast to our hypothesis and results
432 from our previous epigenome-wide study on the effects of perinatal *L. reuteri* treatment on cord
433 blood CD4+ cells³⁹, a larger proportion of the CpG sites were hypermethylated when
434 comparing either of the intervention groups to the double placebo group. This finding could
435 have several explanations. First of all, unlike our previous studies investigating possible allergy
436 preventive effects of perinatal probiotic intervention³⁹ or ω -3 intervention^{16,17} the combined
437 intervention was initiated already at gestational (GW) 20 in the PROOM-3 study, compared to
438 GW 25 for ω -3 fatty acid¹⁶ and GW 36 for *L. reuteri*⁵² supplementation in the previous study.
439 Additionally, the maternal dosage of the *L. reuteri* strain was also higher by an order of
440 magnitude in this study (10^9 colony forming units (CFU), compared to 10^8 CFU previously⁵²),
441 possibly allowing for potentiated effects of the probiotic intervention. Furthermore, we here
442 utilised Illumina's Infinium MethylationEPIC 850K array, surveying more than 866 000 sites all

443 over the genome. Despite including more than 90% of the investigated sites from the previous
444 Illumina 450K platform⁵³, almost twice the amount of DNA methylation probes were
445 investigated. This could possibly explain why the present findings differ from the previous study
446 where the Illumina 450K platform was used. Also, as only autosomal chromosomes were
447 retained the present analyses, this may have affected the outcomes in relation to our previous
448 study³⁹, where all chromosomes were included in the analyses. Altogether, these modifications
449 to the study, experimental and statistical protocol could possibly explain the apparent reversed
450 observations in terms of major hypermethylation upon intervention with *L. reuteri* and/or ω -3
451 fatty acids in this study, in contrast to hypomethylation upon *L. reuteri* intervention previously.³⁹

452 Advantages of the present study include the performance of the DNA methylation analyses in
453 purified CD4+ T cells, cells which are instrumental for development of specific long-term
454 immune responses in general, but also for the development of allergic diseases in particular.²
455 Also, despite our relatively small sample numbers, we are able to evaluate all four intervention
456 groups in this study, enabling us to shed light on treatment-specific effects on the methylome.
457 The performance of network analyses provides another benefit of this study, where the
458 analyses have generated putative candidate genes to study further in an allergy development
459 and prevention context. As the study is still on-going, we were not able to perform any
460 comparisons of the interventions and their respective DNA methylation patterns on outcomes
461 of allergy development. However, we made up for this drawback by comparing our findings to
462 an independent allergy study, where we indeed could show enrichment of our DMCs. Another
463 limitation in our analyses include the lack of validation at the mRNA or protein expression level.

464 In conclusion, we demonstrate that the combined prenatal treatment with *L. reuteri* and/or ω -
465 3 fatty acids results in general differential hypermethylation in neonatal CD4+ T cells, which
466 affects both T cell-specific and immune-related pathways. This was corroborated by network
467 analyses that condensed the findings to differentially methylated genes in linked pathways,
468 which also showed relevance in an independent cohort of allergic disease. Future follow-ups
469 on allergic disease and studies on transcriptional activity will confirm the long-term relevance

470 of the presented findings, which may have an impact on future development of allergy
471 prevention regimens.

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491 **METHODS**

492 **Study participants**

493 In this study, cord blood samples collected at the time of birth were included for 63 children
494 from the on-going randomised double blind placebo-controlled trial PROOM-3
495 (ClinicalTrials.gov-ID: NCT01542970), in which the allergy preventive effects of combined pre-
496 and postnatal *Lactobacillus reuteri* and ω -3 fatty acid supplementation are investigated. The
497 study is four-armed comprising the following groups; double active treatment (L ω , *L. reuteri*
498 and ω -3 fatty acids), single active treatments (placebo for either treatment, active treatment for
499 either *L. reuteri* (LP) or ω -3 (P ω)) and double placebo treatment (PP). In the present study, the
500 following numbers of samples were available per group: L ω = 18, LP = 16, P ω = 15, PP = 14.
501 The mothers are supplemented with the probiotic intervention or the corresponding placebo
502 supplement from GW 20 until delivery, whereas the children receive the same treatment
503 throughout the first year of life. The active probiotic substance consists of *L. reuteri* (BioGaia[®],
504 Stockholm, Sweden) suspended in sun flower and palm kernel oil, which is given as droplets
505 twice daily to the mothers (10⁹ CFU) and once daily to the children (10⁸ CFU). Placebo
506 treatment for the probiotic intervention consists of the same oil mixture as above without
507 probiotics. The ω -3 fatty acid intervention or corresponding placebo supplement are given from
508 GW 20 throughout lactation to the mothers. Twice daily, the mothers ingest either three
509 capsules of Pikasol[®] (Orkla Health, Lund, Sweden, 1 g capsules containing 640 mg ω -3 PUFA,
510 35% EPA, 25% DHA) or the placebo supplement olive oil. The children are followed-up at
511 several occasions using questionnaires and by performance of clinical examinations. As the
512 study still is ongoing, only parent reported questionnaire data from the 3-month follow-up were
513 included for the purpose of this study. Parents or legal guardians provided informed consent
514 on behalf of the children prior to inclusion in the study. Ethical permission for this study has
515 been granted by the Regional Ethics Committee for Human Research in Linköping (Dnr
516 2011/45-31).

517

518 **Cord blood mononuclear cell and CD4+ magnetic bead isolation**

519 The isolation of cord blood mononuclear cells (CBMCs) from cord blood and the following
520 magnetic bead isolation of CD4+ T cells from the CBMCs have been described in detail
521 elsewhere.³⁹

522

523 **Flow cytometry measurements of naïve and memory T cell proportions**

524 In order to determine the proportion of naïve and memory cells from the isolated CD4+ cells
525 0.2×10^6 cells were stained for flow cytometry. Firstly, in order to determine the amount of live
526 and dead cells in each sample Aqua LIVE/DEAD™ Fixable Dead Cell Stain (Invitrogen,
527 Eugene, OR, USA) reconstituted reagent (according to manufacturer's protocol) was diluted
528 1:500 in PBS (Medicago AB, Uppsala, Sweden) + 0.1% FCS (Sigma-Aldrich, Ayrshire, United
529 Kingdom) and added to the samples for 15 minutes at RT. Thereafter, the cells were further
530 stained with CD4 PerCP (SK3) and CD45RA FITC (L48), with a complementary isotype tube
531 including CD4 PerCP and Mouse γ 1 FITC (X40) (all antibodies: Becton-Dickinson, San José,
532 CA, USA) for 15 min at 4°C. After washing the cells, they were resuspended as described
533 previously³⁹ and 10 000 events were collected on a FACS Canto II instrument using the FACS
534 Diva software (version 8.0.1). The flow cytometry data were analysed using Kaluza (version
535 2.1, Beckman Coulter, Indianapolis, IN, USA), and the utilised gating strategy is presented in
536 Figure S7.

537 **DNA extraction**

538 From the remaining CD4+ cells, DNA was extracted using Allprep RNA/DNA Mini Kit (Qiagen,
539 Austin, TX, USA) according to the manufacturer's instructions. DNA concentrations were
540 measured using Qubit dsDNA BR Assay Kit (Thermo Fischer Scientific, Waltham, MA, USA)
541 according to the manufacturer's instructions on a Qubit 3.0 fluorometer device (Thermo Fischer
542 Scientific, Waltham, MA, USA). DNA samples were sent to the SNP&SEQ-technology platform
543 at SciLifeLab (Uppsala University, Uppsala, Sweden) for the performance of Illumina's Infinium

544 Human MethylationEPIC 850K bead chip array preceded by bisulphite conversion on site. The
545 amount of DNA for each sample ranged from 1000-1800 ng.

546

547 **Statistics**

548 As the study is still on-going, the study has not yet been unblinded. An independent statistician
549 has provided the code key only to collaborators that have not been involved in sample
550 collection or laboratory experiments, as not to bias the investigators in interpretation of the
551 data.

552 Descriptive analyses of demographic variables were performed. Continuous variables were
553 tested for normality using the Shapiro-Wilk test of normality followed by Levene's test of equal
554 variances. Thereafter the Kruskal-Wallis H test was performed to study differences in
555 proportions between the groups. For the categorical variables, the Pearson χ^2 test was
556 performed.

557

558 **DNA methylation analyses**

559 The generated raw data from the Illumina 850K MethylationEPIC arrays were processed in
560 GenomeStudio (version 2011.1, Illumina Inc.) by the SNP&SEQ-technology platform, to render
561 IDAT-files manageable for downstream analyses in the R programming environment (version
562 3.6.3).

563

564 **Pre-processing and quality control**

565 The raw DNA methylation data were pre-processed using the ChAMP⁵⁴ package (version
566 2.16.1) for the R programming environment. Probes with detection p-values above 0.01 and
567 multi-hit probes were filtered out, as were non-CpG probes and probes related to SNPs and
568 NA-probes. Furthermore, as we found significantly more females in the single active ω -3

569 treated ($P\omega$) group, and as X-inactivation in females skews the beta value distribution (Figure
570 S8), probes located on the X and Y chromosomes were omitted from the data. After the
571 filtration step, 738 451 CpGs of the initial 865 918 investigated CpGs in the Illumina
572 MethylationEPIC 850K array remained. Thereafter, beta values were calculated for all probes,
573 representing the mean methylation of each CpG site, and to adjust for the inherently different
574 designs of the Illumina DNA methylation arrays, normalisation of the beta values was
575 conducted using the beta mixture quantile (BMIQ) method.⁵⁵ In order to identify the most
576 significant components of variation in the data, and correct for unwanted variation if found,
577 singular value decomposition (SVD) analyses were performed on the filtered and normalised
578 data, using the ChAMP package. Based on results from these analyses, corrections were
579 made in the data for the technical factors array and slide (Figure S9). The quality of the data
580 was examined prior to and after the normalisation step (Figure S10). To ascertain possible
581 differences in cellular content of the included samples, several methods were used to validate
582 the findings. Maternal contamination of the cord blood samples was examined on the unfiltered
583 data using the method proposed by Morin *et al.*⁵⁶ By surveying threshold DNA methylation
584 levels of 10 specified CpG sites, samples with values above the threshold values at five or
585 more sites indicate contamination and should be excluded. Six samples had a beta value
586 above the threshold value at one CpG site and one sample had beta values above the
587 threshold values at two CpG sites (data not shown), indicating no maternal contamination and
588 hence all 63 samples were retained in further downstream analyses. The cell type composition
589 of the samples was evaluated on filtered and normalised samples using the Houseman
590 method.⁵⁷ The majority of cells were CD4+ cells with median proportions in the intervention
591 groups between 94-96% (Table S11), indicating high sample purity and successful isolation of
592 CD4+ T cells. Multidimensional scaling (MDS) analyses were performed on the filtered,
593 normalised and batch corrected data to study inherent differences in the data, using the R
594 package minfi (version 1.32.0). Results of the SVD analyses using the ChAMP package
595 showed that, apart from the sample array and slide, sex was a major source of unwanted
596 variation in the normalised data. Therefore, sex was added as a co-variate in the batch

597 correction step for the data used in the MDS analyses, using the ComBat function⁵⁸ from the
598 sva package⁵⁹ (version 3.34.0), implemented in ChAMP. Following the statistical analyses, the
599 MDS results were graphically represented by assigning the samples to their respective
600 intervention group belonging.

601

602 **Differential DNA methylation analysis**

603 Using the limma package (version 3.42.2), differentially methylated probes were identified by
604 fitting the DNA methylation data to a linear model. As the proportion of males and females in
605 the samples of at least one of the groups was skewed, sex was included as a co-variate in the
606 model, as was the proportion of memory CD4+ T cells in order to account for possible
607 differences in T cell subtypes. Moderated t-statistics, log2 Fold Change (logFC) and p-values
608 were computed for each investigated probe. The logFC values represents the average beta
609 methylation difference (from hereon referred to as mean methylation difference, MMD)
610 between the respective active intervention groups in relation to the double placebo (PP) group.
611 P-values were adjusted for multiple testing using the Benjamini-Hochberg procedure for False
612 Discovery Rate (FDR) correction. Differentially methylated CpGs (DMCs) were defined as
613 probes having an FDR-adjusted p-value of less than 0.1 along with an MMD of > 5%. Volcano
614 plots were constructed to graphically illustrate the distribution of the DMCs using the base R
615 environment. Identification of genes of interest was conducted by mapping the DMCs to the
616 genome, resulting in differentially methylated genes (DMG). The DMGs were defined as genes
617 containing at least one DMC, where hypomethylation was defined as all DMCs being
618 hypomethylated and vice versa for the hypermethylated DMGs. Genes containing both hypo-
619 and hypermethylated sites were considered having a mixed methylation pattern. A total of three
620 differential methylation comparisons were made between each of the treatment groups
621 compared to the double placebo group. The quality of these comparisons was ascertained
622 using several approaches. First of all, the genomic inflation rate was investigated for the t-
623 statistics of each of the three comparisons described above, as the large number of statistical

624 comparisons made within each analysis may render a considerable number of false positive
625 results. The genomic inflation and pertaining bias were estimated and QQ-plots plotting the
626 differential DNA methylation data against a normal distribution were constructed using the R
627 package BACON⁶⁰(version 1.14.0). The estimated inflation values for each of the three
628 comparisons was very close to one in all cases, indicating that there was no substantial
629 genomic inflation in the comparisons (Figure S11), and hence no correction was needed.
630 Pathway enrichment analyses were performed on the identified DMCs from the differential
631 DNA methylation analyses, using the clusterProfiler package (version 3.14.3) and the KEGG
632 PATHWAY database (release 94 2020/04). An adjusted p-value cut-off of 0.1 was chosen to
633 narrow down the number of pathways.

634

635 **Network analyses**

636 To further study the biological relevance of the findings from the differential methylation
637 analyses, the DMCs identified in the different comparisons described above were annotated
638 to their corresponding gene symbols (DMGs) with the Illumina 850K platform annotation
639 reference. A total of 93 deprecated unique gene terms from the platform reference were
640 corrected to the most updated nomenclature using the org.Hs.eg.db R package (version
641 3.10.0). Thereafter, the DMGs were used as seeds to construct the inputs for the disease
642 module identification pipeline with MODifieR⁴⁰ R package (version 0.1.3, available at
643 <https://gitlab.com/Gustafsson-lab/MODifieR>). Four different module defining algorithms from
644 the package were implemented (Clique SuM, DIAMOnD, MCODE and Module Discoverer),
645 and default parameters for the methods were used in each case. High confidence human
646 protein-protein interactions (PPI) were retrieved from the STRING database (version 11.0,
647 confidence score > 0.7). The four MODifieR methods were run for each comparison, resulting
648 in a set of gene lists corresponding to the identified modules. Non-biased consensus modules
649 were created for each comparison, by extracting genes found by all four module inference
650 methods. Network visualisation was conducted in Cytoscape (version 3.7.2). Pathway

651 enrichment analyses were performed on the module specific genes as described above to
652 elucidate the role of the different intervention combinations on the CD4+ T cells. Furthermore,
653 to unravel subclusters within the modules, visual inspection of the networks along with pathway
654 enrichment analyses in the clusterProfiler R package (version 3.14.3, KEGG database) were
655 performed. Clusters with three or more nodes were included in these analyses. Pathway
656 enrichment analyses were also performed for unique and shared genes within the networks.
657 To illustrate overlaps between shared and unique genes in the comparisons, Venn diagrams
658 were constructed using the VennDiagram R package (version 1.6.20). Furthermore, to
659 illustrate how the common genes may differ in methylation status between the comparisons,
660 river plots were constructed using the riverplot R package (version 0.6).

661

662 **Comparisons of differential methylation and network results to publicly available allergy** 663 **data set**

664 As we were interested in the relevance of our findings to allergic disease, but do not yet have
665 any data available on this from the children of the PROOM-3 study, we compared the findings
666 of our study with publicly available data on allergic disease. The chosen data set was
667 downloaded from Gene Expression Omnibus
668 (<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE50222>) and consisted of Illumina
669 450K data from CD4+ T cells from 8 adult patients vs. 8 controls with seasonal allergic rhinitis
670 with samples from both within and out of season (in total 32 samples).⁶¹ The data were pre-
671 processed by removing probes located on the sex chromosomes, and filtering was performed
672 by removing probes having more than 20% NAs and imputing remaining NAs within retained
673 probes using the KNN method (ChAMP, version 2.12.1). Thereafter, the data were normalised
674 using the BMIQ method and SVD analyses followed (Figure S12) as described earlier, showing
675 that no correction was needed. Subsequent differential DNA methylation analyses were
676 performed using the limma package (version 3.42.2), and sex as well as season of sample
677 taking (within or outside of pollen season) were added as co-variates in the linear models.

678 Upon this, a total of 13102 DMCs were found for the data set, which were then compared to
679 DMCs from our differential DNA methylation analyses and DMCs extracted from the genes
680 identified in the respective network modules. Enrichment of any DMCs in these comparisons
681 was performed using the enrichment function from the R package bc3net (version 1.0.4),
682 based on a one-sided Fisher's exact test. As the data set originated from 450K data, the
683 intersection of all 450K probes and all MethylationEPIC 850K probes excluding the sex
684 chromosomes was used as background for the analysis, and only DMCs that were present in
685 the background were included. Corresponding pathway enrichment analyses for genes
686 overlapping between any of the differentially methylated DMCs or consensus module
687 originating DMCs with the allergy data set were performed as described above.

688

689

690

691

692

693

694

695

696

697

698

699

700

701 **ABBREVIATIONS**

702 BMIQ – beta mixture quantile

703 CBMC – cord blood mononuclear cell

704 CFU – colony forming unit

705 CpG – Cytosine-phosphate-Guanine

706 DMC – differentially methylated CpG

707 DMG – differentially methylated gene

708 FDR – false discovery rate

709 GW – gestational week

710 *L. reuteri* – *Lactobacillus reuteri*

711 LP – single-treated *L.reuteri* + placebo group

712 L ω – double-treated *L.reuteri* + ω -3 group

713 MDS – multidimensional scaling

714 MMD – mean methylation difference

715 PBMC – peripheral blood mononuclear cell

716 PP – double placebo group

717 PROOM-3 – PRObiotics and OMega-3 study

718 P ω – single-treated ω -3 + placebo group

719 SVD – singular value decomposition

720 ω -3 – omega-3 fatty acids

721

722 REFERENCES

- 723 1. Blaser MJ. The theory of disappearing microbiota and the epidemics of chronic diseases. *Nature*
724 *Reviews Immunology*. 2017;17:461-463.
- 725 2. Lambrecht BN, Hammad H. The immunology of the allergy epidemic and the hygiene
726 hypothesis. *Nature immunology*. 2017;18:1076-1083.
- 727 3. Simon KA, Hollander GA, McMichael A. Evolution of the immune system in humans from infancy
728 to old age. *Proceedings Biological sciences / The Royal Society*. 2015;282:20143085.
- 729 4. Gollwitzer ES, Marsland BJ. Impact of Early-Life Exposures on Immune Maturation and
730 Susceptibility to Disease. *Trends in immunology*. 2015;36:684-696.
- 731 5. Jenmalm MC. The mother-offspring dyad: microbial transmission, immune interactions and
732 allergy development. *Journal of internal medicine*. 2017;282:484-495.
- 733 6. Macpherson AJ, de Agüero MG, Ganal-Vonarburg SC. How nutrition and the maternal
734 microbiota shape the neonatal immune system. *Nature reviews Immunology*. 2017;17:508-517.
- 735 7. Julia V, Macia L, Dombrowicz D. The impact of diet on asthma and allergic diseases. *Nature*
736 *Reviews Immunology*. 2015;15:308-322.
- 737 8. Dzidic M, Boix-Amorós A, Selma-Royo M, Mira A, Collado M. Gut Microbiota and Mucosal
738 Immunity in the Neonate. *Medical sciences (Basel, Switzerland)*. 2018;6:56.
- 739 9. Renz H, Skevaki C. Early life microbial exposures and allergy risks: opportunities for prevention.
740 *Nature Reviews Immunology*. 2020:1-15.
- 741 10. Miles EA, Calder PC. Can Early Omega-3 Fatty Acid Exposure Reduce Risk of Childhood
742 Allergic Disease? *Nutrients*. 2017;9:784.
- 743 11. Blasbalg TL, Hibbeln JR, Ramsden CE, Majchrzak SF, Rawlings RR. Changes in consumption
744 of omega-3 and omega-6 fatty acids in the United States during the 20th century. *The American*
745 *Journal of Clinical Nutrition*. 2011;93:950-962.
- 746 12. Warstedt K, Duchén K. Increased linoleic acid/ α -linolenic acid ratio in Swedish cord blood
747 samples collected between 1985 and 2005. *European journal of nutrition*. 2012;52:659-665.
- 748 13. Miyata J, Arita M. Role of omega-3 fatty acids and their metabolites in asthma and allergic
749 diseases. *Allergology international : official journal of the Japanese Society of Allergology*.
750 2015;64:27-34.
- 751 14. Krauss-Etschmann S, Hartl D, Rzehak P, *et al*. Decreased cord blood IL-4, IL-13, and CCR4
752 and increased TGF- β levels after fish oil supplementation of pregnant women. *Journal of Allergy*
753 *and Clinical Immunology*. 2008;121:464-470000000.
- 754 15. Bisgaard H, Stokholm J, Chawes BL, *et al*. Fish Oil-Derived Fatty Acids in Pregnancy and
755 Wheeze and Asthma in Offspring. *The New England journal of medicine*. 2016;375:2530-2539.
- 756 16. Furuholm C, Warstedt K, Larsson J, *et al*. Fish oil supplementation in pregnancy and lactation
757 may decrease the risk of infant allergy. *Acta Paediatrica*. 2009;98:1461-1467.
- 758 17. Furuholm C, Warstedt K, Fagerås M, *et al*. Allergic disease in infants up to 2 years of age in
759 relation to plasma omega-3 fatty acids and maternal fish oil supplementation in pregnancy and
760 lactation. *Pediatric Allergy and Immunology*. 2011;22:505-514.
- 761 18. Stokholm J, Blaser MJ, Thorsen J, *et al*. Maturation of the gut microbiome and risk of asthma in
762 childhood. *Nature Communications*. 2018;9:141.
- 763 19. Bisgaard H, Li N, Bonnelykke K, *et al*. Reduced diversity of the intestinal microbiota during
764 infancy is associated with increased risk of allergic disease at school age. *Journal of Allergy*
765 *and Clinical Immunology*. 2011;128:646-65200000.
- 766 20. Sjögren YM, Jenmalm MC, Böttcher MF, Björkstén B, Sverre-remark-Ekström E. Altered early
767 infant gut microbiota in children developing allergy up to 5 years of age. *Clinical and*
768 *experimental allergy : journal of the British Society for Allergy and Clinical Immunology*.
769 2009;39:518-526.
- 770 21. Chiu C-Y, Chan Y-L, Tsai M-H, Wang C-J, Chiang M-H, Chiu C-C. Gut microbial dysbiosis is
771 associated with allergen-specific IgE responses in young children with airway allergies. *The*
772 *World Allergy Organization journal*. 2019;12:100021.
- 773 22. Ling Z, Li Z, Liu X, *et al*. Altered Fecal Microbiota Composition Associated with Food Allergy in
774 Infants. *Applied and Environmental Microbiology*. 2014;80:2546-2554.
- 775 23. Abrahamsson TR, Jakobsson HE, Andersson AF, Björkstén B, Engstrand L, Jenmalm MC. Low
776 diversity of the gut microbiota in infants with atopic eczema. *The Journal of allergy and clinical*
777 *immunology*. 2012;129:434.
- 778 24. Cuello-Garcia CA, Brozek JL, Fiocchi A, *et al*. Probiotics for the prevention of allergy: A
779 systematic review and meta-analysis of randomized controlled trials. *J Allergy Clin*
780 *Immunol*.136.

- 781 25. Wells JM. Immunomodulatory mechanisms of lactobacilli. *Microbial cell factories*. 2011;10
782 Suppl 1.
- 783 26. Abrahamsson TR, Sandberg Abenius M, Forsberg A, Björkstén B, Jenmalm MC. A Th1/Th2-
784 associated chemokine imbalance during infancy in children developing eczema, wheeze and
785 sensitization. *Clinical and experimental allergy : journal of the British Society for Allergy and*
786 *Clinical Immunology*. 2011;41:1729-1739.
- 787 27. Alhamwe B, Alhamdan F, Ruhl A, Potaczek DP, Renz H. The role of epigenetics in allergy and
788 asthma development. *Current Opinion in Allergy and Clinical Immunology*. 2020;20:48-55.
- 789 28. Schmidl C, Delacher M, Huehn J, Feuerer M. Epigenetic mechanisms regulating T-cell
790 responses. *The Journal of allergy and clinical immunology*. 2018;142:728-743.
- 791 29. Zhang H, Kaushal A, Merid S, et al. DNA methylation and allergic sensitizations, a genome-
792 scale longitudinal study during adolescence. *Allergy*. 2019;74:1166-1175.
- 793 30. Peng C, Meel ER, Cardenas A, et al. Epigenome-wide association study reveals methylation
794 pathways associated with childhood allergic sensitization. *Epigenetics*. 2019.
- 795 31. DeVries A, Wlasiuk G, Miller SJ, et al. Epigenome-wide analysis links SMAD3 methylation at
796 birth to asthma in children of asthmatic mothers. *J Allergy Clin Immunol*.
- 797 32. Lund RJ, Osmala M, Malonzo M, et al. Atopic asthma after rhinovirus-induced wheezing is
798 associated with DNA methylation change in the SMAD3 gene promoter. *Allergy*. 2018;73:1735-
799 1740.
- 800 33. Martino D, Dang T, Sexton-Oates A, et al. Blood DNA methylation biomarkers predict clinical
801 reactivity in food-sensitized infants. *J Allergy Clin Immunol*.135.
- 802 34. Martino D, Neeland M, Dang T, et al. Epigenetic dysregulation of naive CD4+ T-cell activation
803 genes in childhood food allergy. *Nature Communications*. 2018;9:3308.
- 804 35. Harb H, Irvine J, Amarasekera M, et al. The role of PKC ζ in cord blood T-cell maturation towards
805 Th1 cytokine profile and its epigenetic regulation by fish oil. *Bioscience Reports*. 2017;37.
- 806 36. Amarasekera M, Noakes P, Strickland D, Saffery R, Martino DJ, Prescott SL. Epigenome-wide
807 analysis of neonatal CD4(+) T-cell DNA methylation sites potentially affected by maternal fish
808 oil supplementation. *Epigenetics*.9.
- 809 37. van Dijk SJ, Zhou J, Peters TJ, et al. Effect of prenatal DHA supplementation on the infant
810 epigenome: results from a randomized controlled trial. *Clinical Epigenetics*. 2016;8:114.
- 811 38. Vähämäki S, Laiho A, Lund R, Isolauri E, Salminen S, Laitinen K. The impact of probiotic
812 supplementation during pregnancy on DNA methylation of obesity-related genes in mothers and
813 their children. *European Journal of Nutrition*. 2018:1-11.
- 814 39. Forsberg A, Huoman J, Söderholm S, et al. Pre- and postnatal Lactobacillus reuteri treatment
815 alters DNA methylation of infant T helper cells. *Pediatric Allergy and Immunology*. 2020.
- 816 40. de Weerd HA, Badam TV, Martínez-Enguita D, et al. MODifieR: an ensemble R package for
817 inference of disease modules from transcriptomics networks. *Bioinformatics (Oxford, England)*.
818 2020;36:3918-3919.
- 819 41. D'Aquila P, Carelli L, Rango F, Passarino G, Bellizzi D. Gut Microbiota as Important Mediator
820 Between Diet and DNA Methylation and Histone Modifications in the Host. *Nutrients*.
821 2020;12:597.
- 822 42. Ceccarelli V, Ronchetti S, Marchetti M, et al. Molecular mechanisms underlying
823 eicosapentaenoic acid inhibition of HDAC1 and DNMT expression and activity in carcinoma
824 cells. *Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms*. 2020;1863:194481.
- 825 43. González-Becerra K, Ramos-Lopez O, Barrón-Cabrera E, et al. Fatty acids, epigenetic
826 mechanisms and chronic diseases: a systematic review. *Lipids in Health and Disease*.
827 2019;18:178.
- 828 44. Salmond RJ, Filby A, Qureshi I, Caserta S, Zamoyska R. T-cell receptor proximal signaling via
829 the Src-family kinases, Lck and Fyn, influences T-cell activation, differentiation, and tolerance.
830 *Immunological Reviews*. 2009;228:9-22.
- 831 45. Kaur S, Bansal Y, Kumar R, Bansal G. A panoramic review of IL-6: Structure, pathophysiological
832 roles and inhibitors. *Bioorganic & Medicinal Chemistry*. 2020;28:115327.
- 833 46. Zhou X, Han X, Lyu S-C, et al. Targeted DNA methylation profiling reveals epigenetic signatures
834 in peanut allergy. *JCI Insight*. 2021.
- 835 47. Baccarelli A, Rusconi F, Bollati V, et al. Nasal cell DNA methylation, inflammation, lung function
836 and wheezing in children with asthma. *Epigenomics*. 2012;4:91-100.
- 837 48. Bruyns E, Marie-Cardine A, Kirchgessner H, et al. T Cell Receptor (TCR) Interacting Molecule
838 (TRIM), A Novel Disulfide-linked Dimer Associated with the TCR-CD3- ζ Complex, Recruits
839 Intracellular Signaling Proteins to the Plasma Membrane. *The Journal of Experimental*
840 *Medicine*. 1998;188:561-575.

- 841 49. Kirchgessner H, Dietrich J, Scherer J, *et al.* The Transmembrane Adaptor Protein Trim
842 Regulates T Cell Receptor (Tcr) Expression and Tcr-Mediated Signaling via an Association with
843 the Tcr ζ Chain. *The Journal of Experimental Medicine*. 2001;193:1269-1284.
- 844 50. Mehta AK, Gracias DT, Croft M. TNF activity and T cells. *Cytokine*. 2018;101:14-18.
- 845 51. Yamada A, Arakaki R, Saito M, Kudo Y, Ishimaru N. Dual Role of Fas/FasL-Mediated Signal in
846 Peripheral Immune Tolerance. *Frontiers in Immunology*. 2017;8:403.
- 847 52. Abrahamsson TR, Jakobsson T, Böttcher MF, *et al.* Probiotics in prevention of IgE-associated
848 eczema: a double-blind, randomized, placebo-controlled trial. *J Allergy Clin Immunol*. 2007;119.
- 849 53. Solomon O, Maclsaac J, Quach H, *et al.* Comparison of DNA methylation measured by Illumina
850 450K and EPIC BeadChips in blood of newborns and 14-year-old children. *Epigenetics*. 2018:1-
851 10.
- 852 54. Tian Y, Morris TJ, Webster AP, *et al.* ChAMP: updated methylation analysis pipeline for Illumina
853 BeadChips. *Bioinformatics (Oxford, England)*. 2017;33:3982-3984.
- 854 55. Teschendorff AE, Marabita F, Lechner M, *et al.* A beta-mixture quantile normalization method
855 for correcting probe design bias in Illumina Infinium 450 k DNA methylation data. *Bioinformatics*
856 *(Oxford, England)*. 2013;29:189-196.
- 857 56. Morin AM, Gatev E, McEwen LM, *et al.* Maternal blood contamination of collected cord blood
858 can be identified using DNA methylation at three CpGs. *Clinical Epigenetics*. 2017;9:75.
- 859 57. Houseman EA, Accomando WP, Koestler DC, *et al.* DNA methylation arrays as surrogate
860 measures of cell mixture distribution. *BMC bioinformatics*. 2012;13:86.
- 861 58. Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using
862 empirical Bayes methods. *Biostatistics (Oxford, England)*. 2007;8:118-127.
- 863 59. Leek JT, Johnson EW, Parker HS, Jaffe AE, Storey JD. The sva package for removing batch
864 effects and other unwanted variation in high-throughput experiments. *Bioinformatics*.
865 2012;28:882-883.
- 866 60. van Iterson M, van Zwet EW, Consortium B, Heijmans BT. Controlling bias and inflation in
867 epigenome- and transcriptome-wide association studies using the empirical null distribution.
868 *Genome Biology*. 2017;18:19.
- 869 61. Nestor CE, Barrenas F, Wang H, *et al.* DNA methylation changes separate allergic patients from
870 healthy controls and may reflect altered CD4+ T-cell population structure. *PLoS Genet*.10.

871

872

873

874

875

876

877

878

879

880

881

882 **DECLARATIONS**

883 *Ethics approval and consent to participate*

884 Parents or legal guardians provided informed consent on behalf of the children prior to
885 inclusion in the study. Ethical permission for this study has been granted by the Regional Ethics
886 Committee for Human Research in Linköping (Dnr 2011/45-31).

887 *Consent for publication*

888 Not applicable

889 *Availability of data and materials*

890 The datasets used and/or analysed during the current study are available from the
891 corresponding author on reasonable request.

892 *Competing interests*

893 The authors report no conflicts of interest.

894 *Funding*

895 This study was supported by grants from the Swedish Research Council (2016-01698 and
896 2019-00989); the Swedish Heart and Lung Foundation (20140321 and 20170365); the
897 Cancer and Allergy Foundation and the Medical Research Council of Southeast
898 Sweden (FORSS-666771 and FORSS-758981).

899 *Author's contributions*

900 M.C.J and K.D. designed the study. K.D. and L.N. were responsible for the clinical evaluation
901 of the children. J.H. has taken part in the sample collection and performed the experimental
902 work presented in this paper. J.E. provided expertise on flow cytometry analyses, and M.G. on
903 the performance of the statistical and bioinformatic analyses. D.M.E., E.O. and J.H. performed
904 the statistical and bioinformatic analyses. J.H. presented the findings. All authors interpreted

905 and discussed the results. J.H. drafted the manuscript. All authors contributed to and approved
906 the final draft for publication.

907 *Acknowledgments*

908 Firstly, we would like to thank the children and mothers included in this study for their
909 participation, and the personnel at the Allergy Center, Linköping for professionally taking care
910 of the families throughout the study period, as well as handling samples in preparation for
911 laboratory work. Our warmest thanks go to our skilled laboratory technicians Camilla Janefjord
912 and Anne-Marie Fornander, for their unfailing collection of samples from the PROOM-3 study.
913 We would also like to thank Simon Söderholm for valuable input in the initial analyses of the
914 DNA methylation data. Lastly, we would like to acknowledge BioGaia® AB and Orkla Health
915 for sponsoring the dietary supplements used in this study, as well as the SNP&SEQ-technology
916 platform at SciLifeLab Uppsala University for yet another constructive collaboration.

917 *Author's information*

918 Not applicable

919

920